Boehringer Ingelheim (BI) obtained a nonexclusive license to ProBioGen's GlymaxX technology for the production of afucosylated antibodies. Fucose-deficient antibodies show enhanced antibody dependent cell-mediated cytoxicity (ADCC) -- typically making them more potent against tumor cells.
The GlymaxX platform enables the production of new and pre-existing producer cell clones and can be engineered in less than 10 weeks. The technology competes against BioWa's (Kyowa Hakko's) Potelligent system for the production of afucosylated antibodies. Presumably both technologies will be competing in oncology applications.
Posted by Bruce Lehr Aug 12th 2011.